Everyone came away happy from the inaugural Tucson Transplant Symposium, hosted Oct. 12 by the Division of Nephrology and Department of Surgery at the University of Arizona College of Medicine – Tucson at the U of A Health Sciences Innovation Building.
See below for a min-photo gallery.
The Saturday morning event focused on the most commonly transplanted organ, kidneys. In 2023, the United Network for Organ Sharing, or UNOS, reported a record 25,498 U.S. kidney transplants completed the prior year. Other transplant records set included livers (9,528), hearts (4,111) and lungs (2,692).
“The symposium was a resounding success,” said Nephrology division Chief Bekir Tanriover, MD, MPH, MBA, FAST. “Our distinguished faculty and transplant staff provided updates on transplant evaluation and processes at our center, addressing hot topics such as the new kidney transplant allocation system (continuous distribution), HCV and HBV NAT positive kidney utilization protocols, disparities in transplantation, and the Living Donor Champion Program.”
Dr. Tanriover thanked Scott Hall, Banner – University Medicine Tucson clinical associate director for the division, pre- and post-kidney transplant provider Ayda Menjugas-McDuff, FNP, and transplant coordinator Samantha Dickson for their “invaluable contributions” that made the symposium possible. Hall reported the event drew nearly 70 pre-registrations and 40 in-person attendees.
Dr. Tanriover added that the HSIB conference room proved to be the perfect venue for the event, which saw significant attendance from local nephrologists in Tucson and Yuma as well as advanced practice providers and nurses from dialysis units. Attendees earned 3.0 CME credits. Representatives from two major nephrology groups in Tucson, the Southwest Kidney Institute and Arizona Kidney Disease & Hypertension Centers, were also present.
EXTRA: Chronic kidney disease in the U.S. & Tucson
Chronic kidney disease, or CKD, affects more than 1 in 7 people – or 14% of adults – in the United States. Estimates from the Center for Disease Control & Prevention put that at about 35.5 million people, many unaware they suffer from it.
CKD cases among Mexican-Americans nearly doubled between 2003-04 and 2015-16, reported JAMA Network Open in 2020. Diabetes and high blood pressure are two main causes of the disease. With end-stage renal failure, sufferers rely on dialysis for artificial filtration of their blood to survive until a transplant may be possible.
“In Tucson, there are an estimated 2,500 end-stage dialysis patients, with nearly 200 listed at our transplant center,” Dr. Tanriover said. “At Banner – University Medical Center Tucson, we have performed 100 kidney transplants (including 10 combined organ transplants) in each of the last two years. Our average waiting time is 1.5-2 years, compared to the national average of 4-5 years.”
Among sponsors and supporters for the Tucson Transplant Symposium were the National Kidney Foundation of Arizona, Donor Network of Arizona, Natera, Merck, Takeda, ThermoFisher, Sanofi, Veloxis Pharmaceuticals, and the U of A Department of Medicine’s Division of Gastroenterology & Hepatology.
After a welcome and introduction, Venkatesh K. Ariyamuthu, MD, FASN, Division of Nephrology associate professor and medical director of the Banner – University Medicine Tucson Kidney Transplant Program, spoke on “How to Prepare CKD Patients for Kidney Transplant.”
Dr. Ariyamuthu was followed by Dr. Tanriover’s address on the “Future of Kidney Transplant Allocation,” in which he described pros and cons of the new system implemented in March 2021 to allocate kidneys for transplant more equitably across the country.
Then, the Division of Nephrology’s Aneesha Shetty, MD, MPH, and Abd Assalam Qannus, MD, went back to back on “Living Donor Kidney Transplantation” and “Biomarkers cfDNA/Gene Expression in Transplants,” respectively.
The symposium closed with clinical pharmacists Ruhani Alam, PharmD, and Alyssa Mutz, PharmD, BCPS, who are part of Surgery’s Abdominal Transplant Multidisciplinary Extended Care Team and spoke on “Benefits of GLP1 agonists and SGLT2 Inhibitors in Renal Transplant Patients.”
MINI-PHOTO GALLERY *
* Click on images to enlarge. Rollover image with mouse for captions.
(Photos courtesy of Scott Hall)